Mach7 Technologies Ltd. (AU:M7T)
ASX:M7T
M7T Stock Chart & Stats
AU$0.56
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.56
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.25 - AU$0.69
Previous CloseN/A
Volume428.94K
Average Volume (3M)368.13K
Market Cap
AU$74.03M
Enterprise ValueAU$57.29M
Total Cash (Recent Filing)AU$18.49M
Total Debt (Recent Filing)AU$1.75M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding235,009,720
10 Day Avg. Volume349,234
30 Day Avg. Volume368,134
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)1.74
Price to Sales (P/S)2.35
P/FCF Ratio701.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.76Price Target Upside35.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$34.50M
Bulls Say, Bears Say
Bulls Say
Enterprise Imaging Market FocusMach7's focus on enterprise medical imaging addresses durable hospital and health-system needs for image storage, viewing and interoperability across radiology and cardiology. This market is structural; enterprise clients have long deployment cycles and high switching costs, supporting sticky revenue and multi-year contracts that sustain business fundamentals over 2-6 months and beyond.
Low Leverage Balance SheetA conservative capital structure with low leverage provides financial flexibility to invest in product development, fund implementations, or absorb near-term cash flow variability without immediate refinancing pressure. Over the medium term this reduces default risk and supports strategic initiatives or targeted M&A if execution requires incremental spending.
Recent Strong Reported Revenue GrowthReported revenue growth of 75.5% indicates accelerating customer adoption and successful sales execution. Sustained top-line expansion helps spread fixed costs, supports investment in R&D and services scale, and creates a runway to improve margins if the company can convert growth into steadier cash generation and operational efficiencies over the next few quarters.
Bears Say
Negative ProfitabilityPersistent negative net profit and EBIT margins signal ongoing operating losses that erode retained capital and limit reinvestment capacity. Without a clear path to sustained positive operating income, the company may need external capital or trade-offs in growth investments, which undermines long-term earnings resilience and investor optionality.
Volatile And Declining Free Cash FlowA recent significant decline in free cash flow growth and low operating cash flow to net income ratio point to weaker cash conversion. Cash flow volatility reduces ability to fund deployments, subscription transitions, or working capital needs internally, raising the likelihood of capital raises or constrained investment over the medium term.
Low Gross And Operating MarginsImproved but still low gross margins suggest structural cost or pricing challenges in the mix of software, services, and migrations. Limited margin headroom constrains operating leverage benefits from revenue growth, making it harder to reach sustainable profitability even as revenue rises, and increasing sensitivity to competitive pricing or cost inflation.
Mach7 Technologies News
M7T FAQ
What was Mach7 Technologies Ltd.’s price range in the past 12 months?
Mach7 Technologies Ltd. lowest share price was AU$0.24 and its highest was AU$0.69 in the past 12 months.
What is Mach7 Technologies Ltd.’s market cap?
Mach7 Technologies Ltd.’s market cap is AU$74.03M.
When is Mach7 Technologies Ltd.’s upcoming earnings report date?
Mach7 Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 149 days.
How were Mach7 Technologies Ltd.’s earnings last quarter?
Mach7 Technologies Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.024 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.019.
Is Mach7 Technologies Ltd. overvalued?
According to Wall Street analysts Mach7 Technologies Ltd.’s price is currently Undervalued.
Does Mach7 Technologies Ltd. pay dividends?
Mach7 Technologies Ltd. does not currently pay dividends.
What is Mach7 Technologies Ltd.’s EPS estimate?
Mach7 Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mach7 Technologies Ltd. have?
Mach7 Technologies Ltd. has 235,009,720 shares outstanding.
What happened to Mach7 Technologies Ltd.’s price movement after its last earnings report?
Mach7 Technologies Ltd. reported an EPS of -AU$0.024 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Mach7 Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:M7T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mach7 Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.76 (35.71% Upside)
AU$0.76 (35.71% Upside)
Blogger Sentiment
Bullish
AU:M7T Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$184.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.50%
12-Months-Change
Fundamentals
Return on Equity
-23.86%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Mach7 Technologies Ltd.
Mach7 Technologies (M7T) is a global provider of advanced imaging solutions, specializing in medical imaging and data management technologies. The company operates primarily in the healthcare sector, focusing on enhancing the efficiency and accessibility of imaging workflows for hospitals, radiology departments, and imaging centers. M7T's core products include enterprise imaging solutions, cloud-based storage, and advanced data analytics, all designed to optimize the management and distribution of medical images and related data.
M7T Company Deck
M7T Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a constructive operational pivot: management presented a clear strategic reset, measurable cost reductions (payments down 9% YoY, 6% QoQ), stronger cash flow (positive operating cash flow in Q2), a stable ARR run rate of $23M, and early commercial/product milestones (first Flamingo customer, CE certificate). These positives are tempered by a near-term reduction in CARR of $2.9M (removal of the NTP project), the strategic exit from the VHA program that reduced backlog but improves long-term margin prospects, lingering VNA/KLAS performance work that may take 12–24 months to fully resolve, and a CTO search following the CIO departure. Overall, the highlights (stabilized ARR, improved cash and cost discipline, new product momentum and regulatory/market expansion) outweigh the lowlights, although several improvements will take time to flow through revenue.View all AU:M7T earnings summariesM7T Stock 12 Month Forecast
Average Price Target
AU$0.76
▲(35.71% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---